News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE)’s Crizotinib Receives Positive Opinion for Conditional Marketing Authorization From the Committee for Medicinal Products for Human Use for the Treatment Of Adults With Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer in the EU



7/20/2012 10:10:25 AM

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU), for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES